Dr. Chari Discusses Carfilzomib Dosing in Myeloma

Ajai Chari, MD
Published: Tuesday, Dec 04, 2018



Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses carfilzomib (Kyprolis) dosing in the treatment of patients with multiple myeloma.

The dose schedule, duration of infusion, and combination therapy are the most important factors to consider when using carfilzomib as a treatment for patients with myeloma, Chari says. At Mount Sinai, Chari says that every patient receiving carfilzomib is infused over 30 minutes, so there is no room for confusion of dosing versus time of infusion.

The drugs that are being given in combination with carfilzomib are also an important consideration, Chari says. Doses of carfilzomib beyond 56 mg should probably not be given in combination with immunomodulatory agents such as lenalidomide (Revlimid) and pomalidomide (Pomalyst), Chari cautions. Although, a dose of 70 mg should be safe with monoclonal antibodies, so the type of agent is important to consider, as well.
SELECTED
LANGUAGE


Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses carfilzomib (Kyprolis) dosing in the treatment of patients with multiple myeloma.

The dose schedule, duration of infusion, and combination therapy are the most important factors to consider when using carfilzomib as a treatment for patients with myeloma, Chari says. At Mount Sinai, Chari says that every patient receiving carfilzomib is infused over 30 minutes, so there is no room for confusion of dosing versus time of infusion.

The drugs that are being given in combination with carfilzomib are also an important consideration, Chari says. Doses of carfilzomib beyond 56 mg should probably not be given in combination with immunomodulatory agents such as lenalidomide (Revlimid) and pomalidomide (Pomalyst), Chari cautions. Although, a dose of 70 mg should be safe with monoclonal antibodies, so the type of agent is important to consider, as well.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x